[A20-89] Talazoparib (breast cancer) - Addendum to Commission A20-48
Last updated 20.11.2020
Project no.:
A20-89
Commission:
Commission awarded on 06.10.2020 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
| Adults with BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer |
Result of dossier assessment:
| Conclusion of dossier assessment A20-48 unchanged: hint of considerable added benefit |
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A20-48 | Talazoparib (breast cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |